Key Sequencing Services and Genetics Test
CRYSTA-NIPT- NON-INVASIVE PRE-NATAL TESTING
Redcliffe Life Science combines Next Generation Sequencing (NGS) with the latest analysis procedure to conduct various genetic test services, including the prenatal gene test for pregnant women and individual health management test and cancer test, from which we can know whether the baby is perfectly healthy or whether the individual is vulnerable to diseases. With the gene test, we can also determine the epigenetic codes and learn the health conditions of individuals, so as to assist in preparing for their future medical state and improve life quality.
In addition to NIPT, we can test for micro-deletions too.Microdeletion syndromes are caused by the deletion of small portion of genetic material during chromosome duplication. In general, the loss of the genetic material carry risks to childs health and development, such as congenital heart defect, delay development of cognitive impairment, autoimmune disease, etc. Yourgene offer NIPT+ – Microdeletion screen test that includes screening for up to 20 Microdeletions.
CRYSTA-Preimplantation Genetic Diagnosis (PGD)/Screening (PGS) With IVF
CRYSTA-PGS (Preimplantation genetic screenings now available for:
- Beta Thalessemia Trait
- Sickle Cell
- Cystic Fibrosis
- SMA 1
- Tay Sachs
- Fragile X
CRYSTA-ONC Hereditary Cancer Testing
Common Hereditary Cancers Panel analyzes over 400 genes associated with cancers of the breast, ovary, uterus, prostate, and gastrointestinal system, which includes the stomach, colon, rectum, small bowel, and pancreas. The panel is designed to maximize diagnostic yield for individuals with a personal or family history of mixed cancers affecting these organ systems.
Genetic testing of these genes may confirm a diagnosis and help guide treatment and management decisions. Identification of a disease-causing variant would also guide testing and diagnosis of at-risk relatives. This test is specifically designed for heritable germline mutations and is not appropriate for the detection of somatic mutations in tumor tissue.
Redcliffe offers testing of Inherited Disorders Focused Exome Testing across over 6000 genes validated using a highly targeted design that enables analysis of only the disease associatedtargets providing deep coverage even on a benchtop sequencer. This design provides 20 or more reads for 95% of targets at 1.5Gb (100x) of sequencing and 98% of targets with 3Gb (200x) of sequencing enabling superior coverage of disease-associated regions making it the ONLY panel across PAN India that offers the most extensive coverage.
Clinical Oncology and Liquid-Biopsy (Blood)
Only testing facility in India on lines of FDA Genetic profiling of FFPE cancer tissue samples, Blood Plasma and more. All tests are conducted by targeted next-generation sequencing (NGS) and is now becoming a daily routine in oncology clinical applications.
- Simultaneous detection of hundreds of variants across hundred of genes relevant to solid tumors
- Targets relevant hotspots, SNVs, indels, CNVs, and gene fusions from DNA or RNA in a single workflow
- Includes solid tumor genes targeted by on-market oncology drugs and published evidence
- Content driven by the Knowledgebase, similar to the FDA panel which includes content aligned to approved therapies and indications.